open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:
Get Citation

75. Validity of accelerated hyperfractionated conformal radiation therapy and monitoring of treatment results in patients with advanced NSCLC. Assessment of tolerance and early failure

B. Jochymek, M. Dybek, A. Radkowski, M. Gawlikowicz
DOI: 10.1016/S1507-1367(01)70445-2
·
Rep Pract Oncol Radiother 2001;6(1):61.

open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:

Abstract

Aim

The assessment of the early failure and toxicity of treatment for the advanced NSCLC using the accelerated hyperfractional conformal irradiation

Material

13 patients (12 men, 1woman, aged 50 – 74), in good performance status/70–90 points of Karnofsky scale/were treated.

Patients have been irradiated with 15 MV or 6 MV photon two times a day with 6 hours break using 1.25 Gy fraction to total dose 50 Gy. PTV ranged from 599 to 1104 cm3 (mean 858 cm3).

Methods

The mean tumor dimension before and 6 weeks after finishing treatment with the use of CT have been assessed.

Results

3 early failure have been observed, all outside of PTV. The 2/3 of that recurrence have been recognized by CT. These patients have been ordered to chemotherapy. The mean tumor dimension was equal to 2,38 cm 6 weeks after finishing of treatment. This means 44% regression of the mean tumor dimension. No side effects and deteriorations of performance status have been observed.

All patients have finished the treatment, all are in follow up, alive.

Conclusions

The accelerated hyperfractioned regimen can be carried out in outpatients service if PTV is smaller than 1000 cm3.

Observed early recurrence two months of follow up are connected with a progression of a tumor outside of irradiated volume.

Abstract

Aim

The assessment of the early failure and toxicity of treatment for the advanced NSCLC using the accelerated hyperfractional conformal irradiation

Material

13 patients (12 men, 1woman, aged 50 – 74), in good performance status/70–90 points of Karnofsky scale/were treated.

Patients have been irradiated with 15 MV or 6 MV photon two times a day with 6 hours break using 1.25 Gy fraction to total dose 50 Gy. PTV ranged from 599 to 1104 cm3 (mean 858 cm3).

Methods

The mean tumor dimension before and 6 weeks after finishing treatment with the use of CT have been assessed.

Results

3 early failure have been observed, all outside of PTV. The 2/3 of that recurrence have been recognized by CT. These patients have been ordered to chemotherapy. The mean tumor dimension was equal to 2,38 cm 6 weeks after finishing of treatment. This means 44% regression of the mean tumor dimension. No side effects and deteriorations of performance status have been observed.

All patients have finished the treatment, all are in follow up, alive.

Conclusions

The accelerated hyperfractioned regimen can be carried out in outpatients service if PTV is smaller than 1000 cm3.

Observed early recurrence two months of follow up are connected with a progression of a tumor outside of irradiated volume.

Get Citation
About this article
Title

75. Validity of accelerated hyperfractionated conformal radiation therapy and monitoring of treatment results in patients with advanced NSCLC. Assessment of tolerance and early failure

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 6, No 1 (2001)

Pages

61

Published online

2001-01-01

DOI

10.1016/S1507-1367(01)70445-2

Bibliographic record

Rep Pract Oncol Radiother 2001;6(1):61.

Authors

B. Jochymek
M. Dybek
A. Radkowski
M. Gawlikowicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl